Studies available to patients with von Willebrand Disease
PPG-VWD uses laboratory values, bleeding history, and genetic testing to compare genetic mutations with the clinical manifestation and management of VWD in families. Definitive diagnoses guides the management of VWD patients, particularly during surgery or severe trauma, underscoring the importance of testing within families.
Comparative Effectiveness in the Diagnosis of VWD
Comparative Effectiveness in the Diagnosis of VWD compares the accuracy of VWD diagnosis prospectively over a 5 year period. The Quantitative Bleeding Score (QBS) of each participant and central comparative laboratory testing (initially blinded and then unblinded) form a cooperative quality control program.
Recombinant Von Willebrand Factor Product
Recombinant von Willebrand Factor Product is being investigated for hemostatic efficacy and safety, with or without ADVATE, in the treatment and control of nonsurgical bleeding events in pediatric subjects diagnosed with severe, hereditary von Willebrand disease. The pharmacokinetic (PK) profile of the product will also be evaluated, as well as its effectiveness in elective and emergency surgery.
Call us for more information about an IHTC Research Study. Our staff will be happy to discuss study eligibility and enrollment requirements.